NUSSLOCH, Germany, August 7, 2014 /PRNewswire/ --
- Leica Biosystems announces a collaboration with Bristol-Myers Squibb to develop companion diagnostic tests in support of targeted therapeutics
- Leica Biosystems will develop fully automated tissue-based companion diagnostic tests to run on the BOND™ automated advanced staining systems
Leica Biosystems, today announced an agreement with Bristol-Myers Squibb Company (NYSE: BMY) to collaborate on developing companion diagnostics on the Leica BOND system for use as an aid in selecting patients for treatment with certain pharmaceuticals developed, or to be developed, by Bristol-Myers Squibb. Other terms of the agreement were not disclosed.
"We are pleased to be working with Bristol-Myers Squibb, on diagnostics for cancer and other therapies on the Leica BOND platform," added Matthias Weber, President of Leica Biosystems, MD. "This partnership is an example of Leica's continued growth in Companion Diagnostics. In this field the capabilities to supply high quality In Vitro Diagnostic products are critical requirements. The ease of use and high staining quality of our BOND systems makes them ideal platforms on which to deploy these very informative tests."
About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients' lives. Leica Biosystems provides anatomic pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Leica's easy-to-use and reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in seven countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Further information can be found at LeicaBiosystems.com.
SOURCE Leica Biosystems